You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. ADAPTABLE RASTERSTEREOGRAPHIC CORNEAL TOPOGRAPHY SYSTEM

    SBC: ELECTROSONICS MEDICAL INC            Topic: N/A

    DESCRIPTION (provided by applicant): A unique technology has been developed by PAR Vision Systems for measuring corneal surface shape that is not reliant on specular reflection and therefore not dependant on high quality optical surfaces or strict alignment criteria. The system developed was an elevation system measuring corneal height directly rather than indirectly through slope measurements use ...

    SBIR Phase II 2003 Department of Health and Human ServicesNational Institutes of Health
  2. Adenylyl Cyclase Type 5 Inhibition to Treat Myocardial Infarction

    SBC: VASADE BIOSCIENCES, INC.            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT The most significant advance in the treatment of Myocardial Infarction (MI) has been reperfusion therapy, which must be applied immediately after the MI diagnosis has been made. Despite the thousands of studies on drug therapies designed to reduce the size of the MI, most have failed in clinical trials. Our hypothesis is that a major reason why these drugs failed is that t ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Advanced Lightweight NBC Protective Clothing

    SBC: UTILITY DEVELOPMENT CORP            Topic: N/A

    N/A

    SBIR Phase II 2003 Department of DefenseSpecial Operations Command
  4. A first-in-class orally active anti-TNF-alpha inhibitor to treat AD

    SBC: P2D, INC            Topic: NIA

    ABSTRACT The goal of this proposal is to develop tumor necrosis factorTNFinhibiting compounds as neuroprotectant drugs for treating Alzheimer s diseaseADCurrent FDA approved AD interventions are symptomatic treatments with limited efficacy which do not affect AD etiology or modify the course of disease progressionThusa critical need exists for a novel AD treatment directed towards AD pathophysiolo ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. 4-(Aminomethyl) benzamides as novel anti-Ebola agents

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    Ebola (EBOV) and Marburg (MARV) viruses belong to the Filoviridae family and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction after an incubation period of 4-14 days. Due to safety concerns, these viruses are designated as biosafety level 4 agents. Currently, there is no effective vaccine or therapeutic treatment for filoviral infections in humans. Africa has recen ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Amorphous Pharmaceutical Product Development Using Containerless Methods

    SBC: MATERIALS DEVELOPMENT INC            Topic: 300

    Amorphous Pharmaceutical Product Development Using Containerless Methods Project Summary The overall objective of this research is to advance drug discovery through precise “engineering” of the structure and properties of API-bearing phases. Many emerging drugs cannot be used in their naturally insoluble crystalline forms or they require crystallization in a preferred polymorph in order to be ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. An Improved Method of Delivering a Sclerosing Agent for the Treatment of a Malignant Pleural Effusion.

    SBC: TDL INNOVATIONS LLC            Topic: 100

    Project Summary / Abstract. We are developing an improved clinical method to treat patients with malignant pleural effusions (MPE), a serious condition that occurs in 150,00-175,000 patients in the US each year, affecting between 7 to 15% of all cancer patients. MPE results in an excessive accumulation of liquid in the pleural cavity, frequently leaving the patient to suffer from shortness of brea ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. An Information Processing Program for High-Risk Parents

    SBC: Psytec Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of the research (Phase I and Phase II) is to design (Phase I) and to evaluate in a clinical trial (Phase II), a time-limited, theoretically and empirically based secondary prevention program (Thoughtful Parenting: Moment to Moment, TPMM) to reduce risk factors associated with the ubiquitous problem of child physical abuse. Specifically, the ...

    STTR Phase II 2003 Department of Health and Human ServicesNational Institutes of Health
  9. A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer

    SBC: Agilvax, Inc.            Topic: 102

    Agilvax’s AX09 is an Immunotherapy for Triple-Negative Breast Cancer: Agilvax is developing cancer immunotherapies and vaccines with its proprietary virus-like-particle (VLP) platform technology. Agilvax’s lead product, AX09, is an immunotherapy for triple-negative breast cancer (TNBC) targeting cancer stem cells (CSC) that is designed for use in combination with existing and emerging therapie ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. A Novel Method for Efficiently and Robustly Retrieving Circulating miRNAs

    SBC: GLC Biotechnology, Inc.            Topic: 400

    Abstract This direct SBIR Phase II project aims to develop a novel technology and associated assays for efficiently and robustly extracting circulating miRNAs from blood (i.e. plasma or serum), which could transform the utility of miRNA testing in the diagnosis and monitoring of major diseases such as cancer and cardiovascular disease. Our competitive advantage lies in the ability to retrieve circ ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government